Peripheral neuropathy supplement protocol — what has trial evidence
Peripheral neuropathy has many causes — diabetes mellitus is the most common, followed by chemotherapy-induced peripheral neuropathy (CIPN), B12 deficiency, alcohol-related, autoimmune, and idiopathic small-fibre presentations. The right supplement strategy depends on the cause. The interventions with the strongest trial evidence — alpha-lipoic acid in diabetic neuropathy, methylcobalamin in B12-related neuropathy, benfotiamine in diabetic and alcoholic presentations — are credible adjuncts. Many widely sold "neuropathy" combination products are not.
What actually works in trials
Alpha-lipoic acid (oral)
600 mg/day, on an empty stomach, ≥12 weeks
The best-evidenced supplement in diabetic peripheral neuropathy. The SYDNEY 2 trial and other RCTs show meaningful reductions in pain, paraesthesia, and numbness scores at 600 mg/day over 5 weeks to 6 months. Higher oral doses (1200, 1800 mg) do not reliably do more and have more GI side effects. The intravenous formulation has a stronger acute-pain effect but is impractical for chronic management. Take on an empty stomach (food meaningfully reduces absorption); discuss with prescriber if on insulin or sulfonylureas (potential additive hypoglycaemia).
Methylcobalamin (or hydroxocobalamin)
1000 mcg sublingual or oral daily; or 1000 mcg IM weekly initially in confirmed deficiency
If B12 deficiency is the cause, supplementation is the treatment. Methylcobalamin is the activated form preferred for neurological repair contexts; cyanocobalamin oral is also effective if dosed adequately (≥1000 mcg/day for malabsorption-related deficiency). IM injection is appropriate for severe deficiency, pernicious anaemia, or post-bariatric surgery presentations. The Sun 2005 trial in diabetic neuropathy showed methylcobalamin's superiority over standard care for symptomatic improvement. Test methylmalonic acid if borderline B12 levels with neuropathy.
Benfotiamine (lipid-soluble thiamine)
300–600 mg/day, in divided doses
A lipid-soluble thiamine derivative with substantially better tissue uptake than standard water-soluble thiamine. Trials in diabetic neuropathy (BENDIP) and alcoholic neuropathy show modest improvements in pain, vibration perception, and neuropathy symptom scores. The mechanism appears to involve transketolase activation and reduction in advanced glycation end-product formation. Generally well-tolerated.
Acetyl-L-carnitine (with caveats — discuss with oncology team first)
1000 mg three times daily
Mixed evidence in CIPN. Some trials in taxane-induced and platinum-induced neuropathy show symptomatic improvement; others have shown no benefit or, concerningly, worse symptoms in long-term follow-up. The Hershman 2013 trial showed worse symptoms at 24 weeks despite initial improvement. Discuss with the oncology team before adding ALCAR in active or recent CIPN. The American Society of Clinical Oncology guideline recommends against routine use of ALCAR for CIPN prevention.
The diabetic neuropathy base
For diabetic peripheral neuropathy, the highest-yield intervention is glycaemic control. Supplements layer on top of this rather than substituting. The base layer:
- Vitamin B12 — particularly important if on chronic metformin (which reduces B12 absorption); test annually after one year on metformin.
- Vitamin D3 to a 30–50 ng/mL target if deficient; some observational data link vitamin D status to neuropathic pain severity.
- Magnesium glycinate 300–400 mg evenings if dietary intake is sub-RDA — small signals on neuropathic pain.
The pain-modulating layer
Pharmacological options (gabapentin, pregabalin, duloxetine, topical capsaicin or lidocaine) are typically more effective than supplements for established neuropathic pain. Supplement-side options that have small signals:
- Magnesium glycinate — modest signals; well-tolerated long term.
- Topical capsaicin 0.025–0.075% — over-the-counter; small but reproducible benefit; takes 2–4 weeks for downregulation effect.
- Curcumin (bioavailable form) — small open-label signals; limited rigorous neuropathy-specific RCTs.
What to skip
- "Nerve renewal" combination products — typically include sub-therapeutic doses of multiple ingredients plus uncharacterised herbal extracts; pay for individual standardised products at trial-cited doses if you're going to use them.
- High-dose vitamin B6 (pyridoxine) — chronic doses above 100 mg/day can cause sensory neuropathy of its own (paradoxical iatrogenic problem). The "B-complex for neuropathy" product space sometimes hides high B6 doses; read labels.
- Mega-dose multivitamin / IV vitamin therapy — no demonstrated benefit specific to peripheral neuropathy; risk of vitamin toxicity with chronic megadosing.
- CBD products marketed for neuropathy — limited neuropathy-specific RCT evidence, highly variable product composition, drug-interaction footprint with central nervous system medications.
- "Nerve repair" stem-cell-promoting supplements — no peripheral neuropathy-specific evidence; the marketing is generally ahead of the trial data.
What to track
The Michigan Neuropathy Screening Instrument (MNSI) or the Neuropathy Symptom Score (NSS) are validated screening tools for monthly self-tracking. Pair with a 0–10 numeric pain score, the impact on sleep, and (if relevant) HbA1c. Reassess at 12–16 weeks of any supplement intervention. A 30%+ reduction in pain score is clinically meaningful; smaller changes are within placebo-noise range.